LT3440105T - T ląstelių receptoriai - Google Patents

T ląstelių receptoriai

Info

Publication number
LT3440105T
LT3440105T LTEPPCT/GB2017/050985T LTGB2017050985T LT3440105T LT 3440105 T LT3440105 T LT 3440105T LT GB2017050985 T LTGB2017050985 T LT GB2017050985T LT 3440105 T LT3440105 T LT 3440105T
Authority
LT
Lithuania
Prior art keywords
cell receptors
receptors
cell
Prior art date
Application number
LTEPPCT/GB2017/050985T
Other languages
English (en)
Inventor
Conor HAYES
Linda HIBBERT
Nathaniel LIDDY
Tara MAHON
Marine RAMAN
Original Assignee
Immunocore Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Limited filed Critical Immunocore Limited
Publication of LT3440105T publication Critical patent/LT3440105T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
LTEPPCT/GB2017/050985T 2016-04-08 2017-04-07 T ląstelių receptoriai LT3440105T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606009 2016-04-08
PCT/GB2017/050985 WO2017175006A1 (en) 2016-04-08 2017-04-07 T cell receptors

Publications (1)

Publication Number Publication Date
LT3440105T true LT3440105T (lt) 2022-05-25

Family

ID=58548761

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/GB2017/050985T LT3440105T (lt) 2016-04-08 2017-04-07 T ląstelių receptoriai

Country Status (29)

Country Link
US (2) US11505590B2 (lt)
EP (2) EP3440105B1 (lt)
JP (1) JP7254519B2 (lt)
KR (1) KR102473964B1 (lt)
CN (1) CN109563148B (lt)
AU (2) AU2017246693B2 (lt)
BR (1) BR112018070741A2 (lt)
CA (1) CA3020214A1 (lt)
CL (1) CL2018002859A1 (lt)
CO (1) CO2018011972A2 (lt)
CR (1) CR20180531A (lt)
DK (1) DK3440105T3 (lt)
ES (1) ES2914648T3 (lt)
HR (1) HRP20220865T1 (lt)
HU (1) HUE059159T2 (lt)
IL (2) IL262144B2 (lt)
LT (1) LT3440105T (lt)
MA (1) MA44608B1 (lt)
MD (1) MD3440105T2 (lt)
MX (1) MX2018012318A (lt)
MY (1) MY198621A (lt)
PE (1) PE20190335A1 (lt)
PH (1) PH12018502158A1 (lt)
PL (1) PL3440105T3 (lt)
PT (1) PT3440105T (lt)
RS (1) RS63371B1 (lt)
SG (1) SG11201808797XA (lt)
SI (1) SI3440105T1 (lt)
WO (1) WO2017175006A1 (lt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117603339A (zh) * 2016-04-08 2024-02-27 艾达普特免疫有限公司 T细胞受体
KR20190065189A (ko) * 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
SG11202002728VA (en) 2017-10-03 2020-04-29 Juno Therapeutics Inc Hpv-specific binding molecules
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
CN112585276A (zh) * 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
HRP20240176T1 (hr) 2019-01-17 2024-04-12 Immunocore Limited Formulacije
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CN114585646A (zh) * 2019-06-18 2022-06-03 里珍纳龙药品有限公司 Mage-a4 t细胞受体及其使用方法
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
EP4076666A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/mage-a4
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
AU2021275049A1 (en) * 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230169944A (ko) 2021-03-09 2023-12-18 씨디알-라이프 아게 Mage-a4 펩티드-mhc 항원 결합 단백질
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
TW202328212A (zh) 2021-12-01 2023-07-16 英商英美偌科有限公司 Ｍａｇｅ—ａ４陽性癌症之治療
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 一种识别mage的高亲和力t细胞受体及其应用
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US20240092859A1 (en) 2022-08-18 2024-03-21 Immunocore Ltd T cell receptors and fusion proteins thereof
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
KR100712256B1 (ko) 1997-10-02 2007-04-27 알토 바이오사이언스 코포레이션 가용성 단일쇄 ｔ-세포 수용체 단백질
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
EP2287185A3 (en) 1999-12-06 2012-10-10 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
JP4436319B2 (ja) 2002-10-09 2010-03-24 メディジーン リミテッド 単鎖組換えｔ細胞レセプター
NZ539226A (en) 2002-11-09 2008-09-26 Medigene Ltd T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
EP2301964A1 (en) 2005-04-01 2011-03-30 Immunocore Ltd. High affinity HIV T cell receptors
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
PT3392270T (pt) 2011-09-15 2020-11-24 Us Health Recetores de células t que reconhecem mage restrito a hlaa1 ou hla-cw7
JP2015502915A (ja) * 2011-10-14 2015-01-29 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ＣＤ１ｄに対する抗体
WO2013063361A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Genetically modified t cell receptor mice
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
SI2951202T1 (sl) * 2013-01-29 2020-08-31 Max Delbrueck Centrum fuer Molekulare Medizin (MDC) Berlin-Buch Vezavne molekule z visoko avidnostjo, ki prepoznajo mage-A1
WO2014160030A2 (en) 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
WO2016007570A2 (en) * 2014-07-09 2016-01-14 The Regents Of The University Of California Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
CN107980046B (zh) 2015-04-13 2021-12-24 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
CN116731156A (zh) 2016-03-16 2023-09-12 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的转染t细胞和t细胞受体
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use

Also Published As

Publication number Publication date
BR112018070741A2 (pt) 2019-02-12
PH12018502158A1 (en) 2019-07-15
MD3440105T2 (ro) 2022-09-30
US20190092834A1 (en) 2019-03-28
AU2017246693A1 (en) 2018-11-22
EP4023668A1 (en) 2022-07-06
JP7254519B2 (ja) 2023-04-10
MA44608B1 (fr) 2022-06-30
CL2018002859A1 (es) 2019-04-26
SG11201808797XA (en) 2018-11-29
CR20180531A (es) 2019-06-13
MA44608A (fr) 2019-02-13
RU2018135248A (ru) 2020-05-12
CN109563148A (zh) 2019-04-02
HUE059159T2 (hu) 2022-10-28
PE20190335A1 (es) 2019-03-07
MY198621A (en) 2023-09-11
ES2914648T3 (es) 2022-06-15
KR102473964B1 (ko) 2022-12-06
WO2017175006A1 (en) 2017-10-12
RS63371B1 (sr) 2022-08-31
US20230322895A1 (en) 2023-10-12
SI3440105T1 (sl) 2022-07-29
PT3440105T (pt) 2022-05-31
EP3440105A1 (en) 2019-02-13
IL308831A (en) 2024-01-01
RU2018135248A3 (lt) 2020-09-23
HRP20220865T1 (hr) 2022-10-14
DK3440105T3 (da) 2022-06-13
CN109563148B (zh) 2022-10-14
EP3440105B1 (en) 2022-04-27
PL3440105T3 (pl) 2022-08-29
US11505590B2 (en) 2022-11-22
KR20180132844A (ko) 2018-12-12
IL262144B2 (en) 2024-04-01
CA3020214A1 (en) 2017-10-12
AU2022256131A1 (en) 2022-11-24
IL262144A (en) 2018-11-29
MX2018012318A (es) 2019-07-04
CO2018011972A2 (es) 2019-02-08
IL262144B1 (en) 2023-12-01
AU2017246693B2 (en) 2022-07-21
JP2019516357A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
IL262144A (en) t cell receptors
ZA201806866B (en) T cell receptors
ZA201806862B (en) T cell receptors
IL271435A (en) t cell receptors
ZA201806865B (en) T cell receptors
IL264425B1 (en) t cell receptors against kras-g20
IL251524B (en) t cell receptors
GB201522592D0 (en) T cell receptors
LT3433270T (lt) T ląstelių receptoriai
GB201518991D0 (en) T cell receptors